Linnen v. A.H. Robins Co.

11 Mass. L. Rptr. 16
Massachusetts Superior Court·Decided December 14, 1999·No. No. 97-2307·Published

Opinion

Brassard, J.

On November 4 and 5, 1999, this matter was before the court on the motion of defen[17]*17dants A.H. Robins Co. (“Robins”) and Wyeth-Ayerst Laboratories (“Wyeth”), divisions of American Home Products, Inc. (“AHP”); and Fisons Corporation (“Fisons”) to exclude expert opinion testimony of the plaintiffs’ pathology expert, Dr. Eugene Mark (“Dr. Mark”). Both parties submitted extensive filings to the court and presented comprehensive oral arguments. Defendants seek to exclude Dr. Mark’s expert testimony concerning autopsy materials that were lost or destroyed before those materials could be examined by defense experts, and any opinions based on those materials as to the cause of death of Mary Linnen (“Ms. Linnen”), the deceased daughter of plaintiffs Thomas and Mary J. Linnen (“the Linnens”).

The materials at issue include certain body organs (lungs, heart, brain and kidney); stock tissues;3 paraffin blocks;4 and blood and other body fluids. In opposition to the motion, plaintiffs argue that a spoliation remedy is inappropriate because Dr. Mark himself neither lost nor destroyed any of the autopsy materials and, in addition, that any prejudice from the absence of the missing materials is de minimis because defendants have had access to adequate medical and pathological information to evaluate the cause of Ms. Linnen’s death.

For the following reasons, the motion is ALLOWED in part and DENIED in part.

BACKGROUND

Thirty-year-old Ms. Linnen was admitted to Quincy City Hospital in cardiac arrest at 7:18 p.m. on February 22, 1997, and was pronounced dead at 7:30 p.m. The Office of the Chief Medical Examiner (“OCME”) assumed responsibility for the autopsy, which was performed at the Massachusetts General Hospital (“MGH”) on the afternoon of February 25, 1997, by a resident, Dr. Howard Chang (“Chang”). The autopsy was supervised by Dr. Mark, the Chief of Pathology at the MGH, in his capacity as the District Medical Examiner for the OCME. Ms. Linnen’s death certificate was signed by OCME on March 21, 1997.

On the day of the autopsy, February 25, 1997, plaintiffs’ counsel sent Dr. Mark an unsolicited letter stating that Ms. Linnen had been taking “Phen Fen” appetite suppressant drugs in the month preceding the onset of her symptoms, and reminding Dr. Mark that “a causal nexus” had been found between those drugs and primary pulmonary hypertension (“PPH”) in the medical literature. The letter requested that Dr. Mark preserve certain pathology materials from the autopsy for examination by the plaintiffs’ independent medical experts. The requested autopsy materials included generous tissue samples from all involved organs and body parts, including the heart, lungs and liver. In addition, Dr. Mark was asked to rule out all possible secondary causes for Ms. Linnen’s death.5

After the autopsy, Dr. Mark ordered that certain pathology materials be preserved. The materials included Ms. Linnen’s lungs and heart, stock tissue, 38 paraffin blocks of representative sections of each organ, numerous slides prepared from the paraffin blocks, and photographs of certain organs and slides, as well as photographs of Ms. Linnen’s body.

At a subsequent pathology conference, a tray of autopsy tissues was presented to MGH pathologists, interns and residents for observation and discussion. After the conference, many of the autopsy materials became unavailable, and their whereabouts remains unknown.

In 1997, the defendants began to pursue the MGH and OCME for pathology materials from the autopsy. On November 28, 1997, in response to an inquiry from OCME about what Linnen tissue specimens were present at MGH, Dr. Mark reported in a memo to OCME that MGH had 37 paraffin blocks, 30 microscopic slides, a set of kodachromes created by photographing the slides through the microscope, and four sets of slides made from additional cuts from the paraffin blocks (“recut slides”).6 Dr. Mark testified at his deposition that he delivered these autopsy materials to OCME shortly after he wrote the memo. The memo did not indicate that any organs or stock tissue from the Linnen autopsy were present at the MGH on November 28, 1997.

Dr. Mark maintains that it is standard procedure for the MGH to discard organs and stock tissues shortly after the autopsy and pathology conference. However, the chief autopsy technician at MGH, James Taralli (“Taralli”), testified at his deposition that it is the normal procedure at MGH to preserve stock tissues from an autopsy in jars of formaldehyde for two to three years. Taralli further testified that when the storage area becomes full, the stock tissue is discarded in six-month or one-year segments, beginning with the oldest specimens, and that no organs or stock tissue may be discarded without the approval of Dr. Mark. In June 1999, although the jars of Ms. Linnen’s stock tissue were no longer available, the stock tissue from other 1996 and 1997 autopsies had not yet been discarded.

By March 24, 1997, one month after the autopsy, Dr. Mark had prepared a draft of an article based on Ms. Linnen’s autopsy for the New England Journal of Medicine (“NEJM’j. The article, titled “Fatal Pulmonary Hypertension Associated with Short-Term Use of Fenfluramine and Phentermine,” was published on August 28, 1997 (337 NEJM 602-6).

On May 5, 1997, the plaintiffs filed suit. On May 13, 1997, defendants’ counsel wrote to plaintiffs’ counsel, requesting that plaintiffs take all necessary steps to ensure that the autopsy materials were preserved. Plaintiffs’ counsel transmitted the request to the OCME, but not to Dr. Mark or to MGH.

On May 21, 1998, plaintiffs’ attorney retained Dr. Mark as an expert witness. In July 1998, defendants [18]*18sought to depose Dr. Mark. On July 29, 1998, Dr. Mark hand-delivered what he believed to be all remaining Linnen pathology materials to OCME’s in-house counsel. To the extent that those materials included organs, stock tissues or 37 of the 38 paraffin blocks from Ms. Linnen’s autopsy, those materials have since become unavailable.7 On January 26, 1999, Dr. Mark stated in a letter to OCME that he had delivered all of the existing pathology materials to OCME.

Between 1997 and 1999, defendants repeatedly sought Ms. Linnen’s organs, blood and tissue specimens from MGH and the OCME for independent testing. Defendants were not informed until February, 1999 that a significant portion of the autopsy materials, including the lungs, heart, tissues, and fluid samples, were no longer available. On February 11, 1999, plaintiffs’ counsel informed defendants’ counsel that limited autopsy materials remained, that the lungs and heart had been discarded by MGH per “usual custom and procedure, ” and that the remaining materials had been delivered to the OCME.

On March 8, 1999, defendants received four sets of 37 or 38 microscopic slides. On June 25, 1999, defendants were notified that Dr. Mark had located one of the missing 38 paraffin blocks, Block A, which contained samples of right kidney tissue. Block A was made available to defendants for examination, slide preparation, and testing. On August 4, 1999, Dr. Mark located, in a research file drawer in his office, a set of 70 additional recut slides he had used to prepare his NEJM article and for other research/medical uses. These slides were made available to defendants.

Free access — add to your briefcase to read the full text and ask questions with AI

Linnen v. A.H. Robins Co., 11 Mass. L. Rptr. 16 (Mass. Ct. App. 1999).

11 Mass. L. Rptr. 16 (Linnen v. A.H. Robins Co.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bolton v. Massachusetts Bay Transportation Authority
593 N.E.2d 248 (Massachusetts Appeals Court, 1992)
Nally v. Volkswagen of America, Inc.
539 N.E.2d 1017 (Massachusetts Supreme Judicial Court, 1989)
Kippenhan v. Chaulk Services, Inc.
428 Mass. 124 (Massachusetts Supreme Judicial Court, 1998)
Carbone v. Checker Taxi Co.
3 Mass. L. Rptr. 240 (Massachusetts Superior Court, 1994)